Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.
The incidence of acute renal failure, defined by the risk, injury, or failure criteria of the RIFLE criteria (risk, injury, failure, loss, and end-stage kidney disease), in 66 patients who received colistimethate sodium was 45%, and 21% of patients stopped therapy because of nephrotoxicity. The RIFLE criteria should be used in the future to allow for comparison of nephrotoxicity among studies.
US Army, Infectious Diseases Service, Walter Reed Army Medical Center, Bldg. 2, Ward 63, 6900 Georgia Ave. NW, Washington, DC 20307, USA. joshua.hartzell@amedd.army.mil
Joshua D
JD
Hartzell
Robert
R
Neff
Julie
J
Ake
Robin
R
Howard
Stephen
S
Olson
Kristopher
K
Paolino
Mark
M
Vishnepolsky
Amy
A
Weintrob
Glenn
G
Wortmann
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy; D003091:Colistin / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015994:Incidence; D007275:Injections, Intravenous; D008297:Male; D051437:Renal Insufficiency / Q000139:chemically induced*; D014481:United States; D028761:Withholding Treatment; D055815:Young Adult
D000900:Anti-Bacterial Agents; C004691:colistinmethanesulfonic acid; D003091:Colistin